GGHC
FULC icon

Gilder Gagnon Howe & Co’s Fulcrum Therapeutics FULC Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-65,600
Closed -$619K – 262
2024
Q1 		$619K Buy
+65,600
New +$586K 0.01% 234

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Gilder Gagnon Howe & Co's FULC Position: Q2 2024 in Review

Gilder Gagnon Howe & Co sold out of Fulcrum Therapeutics (FULC) in Q2 2024, closing a stake of 65,600 shares — an estimated $619K sold.

Gilder Gagnon Howe & Co first reported a position in FULC in Q1 2024 and held it in 1 quarter. The position peaked at $619K in Q1 2024. 121 funds tracked by Wall St. Rank hold FULC as of Q2 2024.

  • Gilder Gagnon Howe & Co reported no remaining Fulcrum Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 65,600 Fulcrum Therapeutics shares in Q2 2024, an estimated $619K.
  • Gilder Gagnon Howe & Co first reported a position in Fulcrum Therapeutics in Q1 2024 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Fulcrum Therapeutics position peaked at $619K in Q1 2024.
  • 121 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2024.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2024, filed 14 Aug 2024.